Literature DB >> 28949784

miR-367 stimulates Wnt cascade activation through degrading FBXW7 in NSCLC stem cells.

Guodong Xiao1, Boxiang Zhang1, Jinying Meng2, Jichang Wang3, Chongwen Xu4, Shou-Ching Tang5,6, Xiang Li1, Jing Zhang1, Rui Liang7, Hong Ren1, Xin Sun1.   

Abstract

Lung carcinoma tops the categories of cancer related motility, and has been treated as the main threat to human health. The functions and related mechanism of FBXW7 controlled lung cancer stem cells' signatures is barely unknown, and the miR-367 regulations of FBXW7 via Wnt signaling have not been explored. Cancer stem cells of either ALDH1+ or CD133+ phenotype were found to be referred to advanced stages in patients with NSCLC (non-small cell lung carcinoma). To study the roles of miR-367, we found greater miR-367 level or FBXW7 level was reserved in NSCLC than that of paired adjacent normal tissues, and their upregulations were positively correlated with Wnt signaling activation. On the contrary, increased miR-367 was correlated with Let-7 repression. MiR-367 was related to stronger sphere forming ability in stem cells of NSCLC. We then explored the functions of the endogenous miR-367 in stem-like cells isolated from NSCLC cell lines. In HEK-293 cells, we identified FBXW7 as the direct downstream gene of miR-367, which consequently released the LIN-28 dependent inhibition of suppressive Let-7. Through informatics analysis, miR-367 was predicated to function through Wnt signaling, and decreased Let-7 played the pivotal role to maintain TCF-4/Wnt pathway activity. The reintroduction of FBXW7 abolished the oncogenic stimulation of miR-367 on TCF-4 activity, with Wnt signaling factors depression. In conclusion, our findings demonstrated the oncogenic roles of miR-367 exerting on the self-renewal ability of cancer stem-like cells through degrading the suppressive FBXW7, eventually helping to maintain Wnt signaling activation through a LIN28B/Let-7 dependent manner.

Entities:  

Keywords:  Cancer stem cells; FBXW7; Let-7; MiR-367; Wnt signaling

Mesh:

Substances:

Year:  2017        PMID: 28949784      PMCID: PMC5788433          DOI: 10.1080/15384101.2017.1380136

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  49 in total

1.  F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner.

Authors:  Kanae Yumimoto; Sayuri Akiyoshi; Hiroki Ueo; Yasuaki Sagara; Ichiro Onoyama; Hiroaki Ueo; Shinji Ohno; Masaki Mori; Koshi Mimori; Keiichi I Nakayama
Journal:  J Clin Invest       Date:  2015-01-02       Impact factor: 14.808

2.  Melanoma miRNA trafficking controls tumour primary niche formation.

Authors:  Shani Dror; Laureen Sander; Hila Schwartz; Danna Sheinboim; Aviv Barzilai; Yuval Dishon; Sebastien Apcher; Tamar Golan; Shoshana Greenberger; Iris Barshack; Hagar Malcov; Alona Zilberberg; Lotan Levin; Michelle Nessling; Yael Friedmann; Vivien Igras; Ohad Barzilay; Hananya Vaknine; Ronen Brenner; Assaf Zinger; Avi Schroeder; Pinchas Gonen; Mehdi Khaled; Neta Erez; Jörg D Hoheisel; Carmit Levy
Journal:  Nat Cell Biol       Date:  2016-08-22       Impact factor: 28.824

3.  MiR-302/367 regulate neural progenitor proliferation, differentiation timing, and survival in neurulation.

Authors:  Si-Lu Yang; Mei Yang; Stephanie Herrlinger; Chen Liang; Fan Lai; Jian-Fu Chen
Journal:  Dev Biol       Date:  2015-10-09       Impact factor: 3.582

Review 4.  Regulation of pluripotency by RNA binding proteins.

Authors:  Julia Ye; Robert Blelloch
Journal:  Cell Stem Cell       Date:  2014-09-04       Impact factor: 24.633

Review 5.  Role of Fbxw7 in the maintenance of normal stem cells and cancer-initiating cells.

Authors:  S Takeishi; K I Nakayama
Journal:  Br J Cancer       Date:  2014-05-22       Impact factor: 7.640

6.  miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF-β signalling pathway.

Authors:  Z Zhu; Y Xu; J Zhao; Q Liu; W Feng; J Fan; P Wang
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

7.  High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer.

Authors:  Minjie Huang; Huijun Zhu; Jian Feng; Songshi Ni; Jianfei Huang
Journal:  Dis Markers       Date:  2015-01-18       Impact factor: 3.434

8.  Circular RNA-ITCH Suppresses Lung Cancer Proliferation via Inhibiting the Wnt/β-Catenin Pathway.

Authors:  Li Wan; Lin Zhang; Kai Fan; Zai-Xing Cheng; Quan-Chao Sun; Jian-Jun Wang
Journal:  Biomed Res Int       Date:  2016-08-24       Impact factor: 3.411

9.  In vitro and in vivo properties of CD133 expressing cells from human lung cancer cell lines.

Authors:  Ping Wang; Zhenhe Suo; Mengyu Wang; Hanne K Høifødt; Oystein Fodstad; Gustav Gaudernack; Gunnar Kvalheim
Journal:  Exp Hematol Oncol       Date:  2013-06-06

Review 10.  Wnt signaling in cancer stem cells and colon cancer metastasis.

Authors:  Sayon Basu; Gal Haase; Avri Ben-Ze'ev
Journal:  F1000Res       Date:  2016-04-19
View more
  14 in total

1.  MiR-146a promotes the asymmetric division and inhibits the self-renewal ability of breast cancer stem-like cells via indirect upregulation of Let-7.

Authors:  Rui Liang; Yuan Li; Meng Wang; Shou-Ching Tang; Guodong Xiao; Xin Sun; Gang Li; Ning Du; Dapeng Liu; Hong Ren
Journal:  Cell Cycle       Date:  2018-07-14       Impact factor: 4.534

2.  FBXW7 suppresses epithelial-mesenchymal transition and chemo-resistance of non-small-cell lung cancer cells by targeting snai1 for ubiquitin-dependent degradation.

Authors:  Guodong Xiao; Yuan Li; Meng Wang; Xiang Li; Sida Qin; Xin Sun; Rui Liang; Boxiang Zhang; Ning Du; Chongwen Xu; Hong Ren; Dapeng Liu
Journal:  Cell Prolif       Date:  2018-08-09       Impact factor: 6.831

3.  CCAT1 stimulation of the symmetric division of NSCLC stem cells through activation of the Wnt signalling cascade.

Authors:  C Xu; G Xiao; B Zhang; M Wang; J Wang; D Liu; J Zhang; H Ren; X Sun
Journal:  Gene Ther       Date:  2018-01-19       Impact factor: 5.250

Review 4.  Circular RNAs as important players in human gastric cancer.

Authors:  F Khanipouyani; H Akrami; M R Fattahi
Journal:  Clin Transl Oncol       Date:  2020-06-25       Impact factor: 3.405

5.  Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis.

Authors:  Yu Hu; Hayley Dingerdissen; Samir Gupta; Robel Kahsay; Vijay Shanker; Quan Wan; Cheng Yan; Raja Mazumder
Journal:  Comput Biol Med       Date:  2018-10-22       Impact factor: 4.589

6.  MicroRNA-671-3p inhibits the development of breast cancer: A study based on in vitro experiments, in-house quantitative polymerase chain reaction and bioinformatics analysis.

Authors:  Dan-Dan Xiong; Hao Chen; Rong-Quan He; Ai-Hua Lan; Jin-Cai Zhong; Gang Chen; Zhen-Bo Feng; Kang-Lai Wei
Journal:  Int J Oncol       Date:  2018-03-28       Impact factor: 5.650

Review 7.  Emerging role of F-box proteins in the regulation of epithelial-mesenchymal transition and stem cells in human cancers.

Authors:  Yizuo Song; Min Lin; Yi Liu; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Stem Cell Res Ther       Date:  2019-04-18       Impact factor: 6.832

8.  Linc00961 inhibits the proliferation and invasion of skin melanoma by targeting the miR‑367/PTEN axis.

Authors:  Xin Mu; Kuan-Hou Mou; Rui Ge; Dan Han; Yan Zhou; Li-Juan Wang
Journal:  Int J Oncol       Date:  2019-07-25       Impact factor: 5.650

9.  Circular RNA YAP1 inhibits the proliferation and invasion of gastric cancer cells by regulating the miR-367-5p/p27 Kip1 axis.

Authors:  Hui Liu; Yuan Liu; Zhaolian Bian; Jing Zhang; Rui Zhang; Xiaoyu Chen; Yanxia Huang; Yang Wang; Jinshui Zhu
Journal:  Mol Cancer       Date:  2018-10-18       Impact factor: 27.401

10.  H19 regulation of oestrogen induction of symmetric division is achieved by antagonizing Let-7c in breast cancer stem-like cells.

Authors:  Meng Wang; Yuan Li; Guo-Dong Xiao; Xiao-Qiang Zheng; Ji-Chang Wang; Chong-Wen Xu; Sida Qin; Hong Ren; Shou-Ching Tang; Xin Sun
Journal:  Cell Prolif       Date:  2018-10-18       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.